Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • Neuigkeiten
  • Über uns
  • Kontakt

Neuigkeiten 2012

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Gilde invests in Pharmaline

20 Dezember 2012 – Gilde has invested in Pharmaline, based in Oldenzaal the Netherlands. Pharmaline is specialized in large scale pharmaceutical compounding. The company is one of the few Dutch players whose facilities and production processes are structured to comply with the guidelines of the Dutch…

Betreffend: Pharmaline

Highlights 2012

20 Dezember 2012 – Season’s Greetings and best wishes for a healthy and prosperous New Year in 2013 from Gilde Healthcare Partners. We look back on an eventful year of successes and a lot of hard work. Click below for our 2012 highlights.

Moximed Initiates US Clinical Study with KineSpring® System in Patients with Knee Osteoarthritis

11 Dezember 2012 – Moximed, Inc. announced today that the KineSpring® System, an implantable medical spring that works by unloading the weight on the diseased knee joint, has been successfully implanted in the first patient enrolled in its US clinical study, SOAR. This prospective, single-arm clinical…

Betreffend: Moximed

Prosonix Elects Dr Ken Cunningham as Non-executive Chairman

5 Dezember 2012 – Prosonix (Oxford, UK), a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its unique particle engineering technology, announces the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been…

Betreffend: Prosonix

Agendia announces discovery of a gene signature that predicts response to a broad range of cancer

27 November 2012 – Gene expression profile could have utility to predict responses to targeted therapies and chemotherapies in multiple cancer types IRVINE, CA and AMSTERDAM, THE NETHERLANDS - Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced…

Betreffend: Agendia

Definiens appoints Dr. Gerald Möller as chairman of its supervisory board

15 November 2012 – Munich, Germany – Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman. Following the recent financing round led by Gilde Healthcare…

Betreffend: Definiens

Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin®

9 Oktober 2012 – Freising, Germany – Pieris AG announced today the achievement of the first financial milestone in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568). The milestone recognizes the…

Betreffend: Pieris Pharmaceuticals Inc.

Moximed's Implantable Knee Spring Successfully Reduces Pain and Quickly Returns Normal Function

9 Oktober 2012 – Clinical Data with the KineSpring® System Released KineSpring System Highlighted at the London Knee Meeting HAYWARD, Calif. & LONDON - KineSpring System Highlighted at the London Knee Meeting. For the millions of patients with mild to moderate knee osteoarthritis (wear), an innovative…

Betreffend: Moximed

Ablynx Reports Excellent Interim Results from Phase I/II Study with its Anti-IL-6R Nanobody, ALX-006

4 Oktober 2012 – 60% of patients in DAS28 remission at week 12 ACR20 score of 80% at week 12 Very encouraging safety profile at all administered doses Rapid onset of activity with some patients achieving remission as early as week 2 GHENT, Belgium — Ablynx [Euronext Brussels: ABLX] today announced…

Betreffend: Ablynx

Ablynx Collaborates with Merck to Develop Therapeutic Nanobody Candidates

2 Oktober 2012 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced a collaboration with Merck & Co., Inc., through a subsidiary, to develop and commercialise Nanobody® candidates directed towards a voltage gated ion channel with the option to develop and commercialise a Nanobody to…

Betreffend: Ablynx

Gilde Healthcare III leads EUR 10 million private financing of Definiens AG

1 Oktober 2012 – Munich, Germany – Definiens AG, the leader in Image Analysis for Digital Pathology, today announced that it has closed a private round of financing of €10 million. The financing was led by Gilde Healthcare Partners. Existing investors including TVM, Cipio and Definiens’ management…

Betreffend: Definiens

Acacia Pharma announces positive results from Phase IIa nausea & vomiting study in cancer patients

1 Oktober 2012 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa proof-of-concept study investigating APD403 for the prevention of acute nausea & vomiting in cancer patients receiving…

Betreffend: Acacia Pharma

Stepping Stones (her)opent villa Oosterveld in Arnhem

21 September 2012 – Arnhem/Elden – Villa Oosterveld met 18 kamers is 21 september officieel geopend door de wethouder van Zorg en Welzijn Henk Kok. Villa Oosterveld is weer open. Het voormalige klooster is nu een Stepping Stones Home & Care zorgvilla voor hulpbehoevende en dementerende ouderen die niet…

Betreffend: Stepping Stones

Ablynx and its Partner Advance NANOBODY Candidate ALX-0751 in Pre-Clinical Development

20 September 2012 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that they have advanced the Nanobody® candidate ALX-0751, together with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, into pre-clinical development in the field of oncology. This is the second pre-clinical…

Betreffend: Ablynx

United Therapeutics Announces Collaboration with Ascendis Pharma to Develop Self-Injectable Treprost

20 September 2012 – SILVER SPRING, Md. - United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis Pharma's proprietary TransCon technology platform to United Therapeutics' treprostinil molecule, the active ingredient…

Betreffend: Acacia Pharma

Ablynx's First Inhaled NANOBODY Successfully Complete Phase 1 Study

18 September 2012 – ALX-0171 has the potential to become a first-in-class therapy   GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically…

Betreffend: Ablynx

Gilde Healthcare Partners Leads USD 17 million Private Financing Round of iWalk, Inc.

14 September 2012 – BEDFORD, Mass – iWalk Inc., the leader in Personal Bionics, announced that it has closed a private equity financing round of $17 million led by Gilde Healthcare Partners. Existing investors, including WFD Ventures, General Catalyst Partners, and Sigma Partners also participated in…

Betreffend: BionX

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck

6 September 2012 – COPENHAGEN, DENMARK – Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting…

Betreffend: Symphogen

UNIQURE obtains recommendation for market approval in Europe of GLYBERA®

20 Juli 2012 – Utrecht, The Netherlands – uniQure (Amsterdam, the Netherlands) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) that recommends marketing authorization of Glybera® (alipogene tiparvovec) as a treatment for…

Betreffend: uniQure

Conatus Pharmaceuticals - Caspase Inhibitor Enters Clinical Trial in Islet Transplantation as Treatm

19 Juli 2012 – SAN DIEGO, CA and EDMONTON, CANADA — Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor. The objective of…

Betreffend: Conatus Pharmaceuticals

Ablynx Announces New Compelling Results on OZORALIZUMAB (ATN-103) in Rheumatoid Arthritis

25 Juni 2012 – Additional Phase II data (ACR20 84%; DAS28 remission 38%) demonstrates that ozoralizumab could have an important competitive and differentiated position in the $24 billion TNFa market Data from the open-label study suggest that ozoralizumab enables individualised treatment, a real…

Betreffend: Ablynx

ProFibrix Enrolls First Patients in Pivotal Phase III Study with Fibrocaps

6 Juni 2012 – Leiden, The Netherlands & Seattle – ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery. FINISH-3…

Betreffend: ProFibrix

Agendia raises $65 million in a private financing round

31 Mai 2012 – Amsterdam, The Netherlands and Irvine, CA – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that the company has raised USD $65 million in a private round of equity financing. The financing round was led by the Debiopharm…

Betreffend: Agendia

Acacia Pharma announces excellent Phase II results for APD421 in post-operative nausea & vomiting

28 Mai 2012 – Cambridge, UK – Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients…

Betreffend: Acacia Pharma

Overname zorgvilla in Doorn afgerond

10 April 2012 – Doorn — De reeds 45 jaar bestaande zorgvilla Nimmerdor Staete op de Julianaweg 47 in Doorn is overgenomen door Stepping Stones Home & Care, bekend in de regio van o.a. Poort van Wijk op de grens tussen Cothen en Wijk bij Duurstede. Niet alleen de eigenaar is veranderd, maar ook de…

Betreffend: Stepping Stones

Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin at the AACR Annual Meeting

4 April 2012 – — Results Support Differentiating Drug-like Features for Targeted Anti-cancer Drug —   Chicago, Illinois — Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company’s proprietary c-Met antagonist program, PRS-110, at the American…

Betreffend: Pieris Pharmaceuticals Inc.

Ablynx Receives Milestone Payment as Novartis Receives IND Approval for a Nanobody in Oncology

2 April 2012 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration…

Betreffend: Ablynx

ProFibrix Achieved All Primary and Secondary Endpoints in US Phase II Study with Fibrocaps™

6 Januar 2012 – LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant…

Betreffend: ProFibrix

Agendia Signs Contract with Blue Shield of California

5 Januar 2012 – IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, an innovative molecular cancer diagnostics company, today announced that the company has signed a contract with Blue Shield of California, making Agendia an in-network provider. The move paves the way for future in-network coverage…

Betreffend: Agendia

ProFibrix US Phase II Study with Fibrocaps™ Meets All Primary and Secondary Endpoints

5 Januar 2012 – LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically…

Betreffend: ProFibrix

Acacia Pharma Initiates Phase II Study with APD421 in Post-Operative Nausea & Vomiting (PONV)

4 Januar 2012 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of a Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant…

Betreffend: Acacia Pharma

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare ist ein spezialisierter europäischer Healthcare-Investor und verwaltet über 1,4 Mrd. EUR (1,5 Mrd. USD) in zwei Fondsstrategien: Private Equity sowie Venture & Growth Capital. Der Private Equity-Fonds von Gilde Healthcare investiert in profitable europäische Gesundheitsunternehmen im Mittelstand und konzentriert sich auf die Benelux- und DACH- Region. Der Private-Equity-Fonds richtet sich an Leistungserbringer und Gesundheitsdienstleister sowie Anbieter von Medizinprodukten im Gesundheitswesen. Der Venture & Growth Capital Fonds von Gilde Healthcare investiert in Medizintechnik, digitale Gesundheit und Therapeutika. Die Venture & Growth-Unternehmen sind in Europa und Nordamerika ansässig.

Investment Philosophie

Gilde Healthcare beteiligt sich an schnell wachsenden, innovativen Unternehmen, die bessere Pflege bei niedrigeren Kosten erbringen.

  • Home
  • Portfolio
  • Team
  • Neuigkeiten
  • Kontakt
  • Impressum
  • Privacy Policy